Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram

Cancer Imaging

Table 1 Patient characteristics in the training and validation datasets

Characteristics	Training dataset (N = 129)	Validation dataset (N = 55)	P
Age^a, median (IQR), years	57 (49–63)	57 (51–61)	0.652
Gender, n (%)			0.673
Male	95 (73.6)	41 (74.5)
Female	34 (26.4)	14 (25.5)
Tumor diameter^a, median (IQR), cm	3.3 (2.5–4.7)	3.5 (2.7–5.2)	0.384
Histological grade, n (%)			0.086
I	31 (24.0)	16 (29.1)
II	66 (51.2)	32 (58.2)
III	32 (24.8)	7 (12.7)
AFP^a, median (IQR)	14.2 (3.6–144.3)	20.5 (4.9–132.3)	0.128
Cause, n (%)			0.467
Alcohol	7 (5.4)	4 (7.3)
HCV	14 (10.9)	6 (10.9)
HBV	106 (82.2)	45 (81.8)
HBV + HCV	2 (1.6)	0
ECOG, n (%)			0.614
0	3 (2.3)	0
1	126 (97.7)	55 (100)
CK19+, n (%)			0.633
0	107 (82.9)	46 (83.6)
1	17 (13.2)	7 (12.7)
2	1 (0.8)	1 (1.8)
3	4 (3.1)	1 (1.8)
GPC3+, n (%)			0.833
0	40 (31)	13 (23.6)
1	47 (36.4)	22 (40)
3	25 (19.4)	9 (16.4)
4	17 (13.2)	11 (20)
HBsAg+, n (%)			0.960
0	74 (57.4)	33 (60)
1	38 (29.5)	20 (36.4)
2	12 (9.3)	2 (3.6)
3	5 (3.9)	0
HBcAg+, n (%)			0.328
0	121 (93.8)	48 (87.3)
1	7 (5.4)	7 (12.7)
2	1 (0.8)	0
Child-Pugh, n (%)			0.102
0	122 (94.6)	55 (100)
1	7 (5.4)	0
BCLC, n (%)			0.382
A	81 (62.8)	27 (49.1)
B1	48 (37.2)	28 (50.9)
Ablation approach			0.175
RFA	86 (66.7)	39 (70.9)
MWA	27 (20.9)	14 (25.5)
CRYO-A	16 (12.4)	2 (3.6)
RFS time^a, median (IQR), months	15 (6–30)	13 (5–36)	0.799

Note: Data are shown as number of patients, with the percentage in parentheses unless noted. No significant differences were found between the training cohort and the validation datasets
^aData are medians, with interquartile ranges in parentheses

ISSN: 1470-7330